首页> 外文期刊>Journal of Personalized Medicine >Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization
【24h】

Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization

机译:眼科个性化医学:从药物遗传学标志物到治疗和剂量优化

获取原文
           

摘要

Rapid progress in genomics and nanotechnology continue to advance our approach to patient care, from diagnosis and prognosis, to targeting and personalization of therapeutics. However, the clinical application of molecular diagnostics in ophthalmology has been limited even though there have been demonstrations of disease risk and pharmacogenetic associations. There is a high clinical need for therapeutic personalization and dosage optimization in ophthalmology and may be the focus of individualized medicine in this specialty. In several retinal conditions, such as age-related macular degeneration, diabetic macular edema, retinal vein occlusion and pre-threshold retinopathy of prematurity, anti-vascular endothelial growth factor therapeutics have resulted in enhanced outcomes. In glaucoma, recent advances in cytoskeletal agents and prostaglandin molecules that affect outflow and remodel the trabecular meshwork have demonstrated improved intraocular pressure control. Application of recent developments in nanoemulsion and polymeric micelle for targeted delivery and drug release are models of dosage optimization, increasing efficacy and improving outcomes in these major eye diseases.
机译:基因组学和纳米技术的飞速发展继续推动我们从诊断和预后到靶向治疗和个性化治疗的患者护理方法。但是,即使有疾病风险和药物遗传学关联的证明,分子诊断学在眼科中的临床应用也受到限制。眼科领域对治疗个性化和剂量优化存在很高的临床需求,并且可能是该专业中个性化医学的重点。在一些视网膜疾病中,例如与年龄有关的黄斑变性,糖尿病性黄斑水肿,视网膜静脉阻塞和早熟阈值视网膜病变,抗血管内皮生长因子治疗剂可提高治疗效果。在青光眼中,影响骨骼流出和小梁网重构的细胞骨架剂和前列腺素分子的最新进展已显示出改善的眼内压控制能力。在纳米乳剂和聚合物胶束中用于靶向递送和药物释放的最新进展的应用是这些主要眼部疾病中剂量优化,提高疗效和改善预后的模型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号